Research Interests

• Dr. Li has dedicated himself to developing innovative treatment for the patients with cancer. In order to accelerate the transformation of scientific and technological achievements, he founded CARsgen Therapeutics company in 2014. He have developed novel technologies and a product pipeline with global rights to address major challenges of CAR-T cell therapies. The product pipeline includes an upgraded fully-human BCMA CAR-T, globally potential first-in-class Claudin18.2CAR-T with the only IND clearance, and globally potential first-in-class GPC3CAR-T. There are eight IND clearances for CAR-T therapies in China, the United States and Canada, ranking the first among all CAR-T companies in China.